Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for ChemoCentryx
Company Monitoring Page for ChemoCentryx
latest headlines for company on cafepharma
Biopharma’s 5 Biggest M&A Deals of 2022
BioSpace
Wed, 12/14/22 - 10:50 am
Tags:
M&A
,
Amgen
,
Horizon Therapeutics
,
Pfizer
,
Biohaven
,
Global Blood Therapeutics
,
Bristol Myers Squibb
,
Turning Point Therapeutics
,
ChemoCentryx
SITC 2022 preview – cytokines and oral checkpoints
EP Vantage
Thu, 10/6/22 - 10:39 am
Tags:
SITC
,
Incyte
,
ChemoCentryx
,
Amgen
,
cytokines
No big bang for biopharma buyouts
EP Vantage
Wed, 10/5/22 - 10:29 am
Tags:
M&A
,
Pfizer
,
Global Blood Therapeutics
,
Amgen
,
ChemoCentryx
,
Novo Nordisk
,
Forma
,
Alcon
,
Aerie Pharmaceuticals
,
Gilead Sciences
,
MiroBio
Amgen, on an M&A spree, inks $3.7B ChemoCentryx buyout to boost inflammatory disease presence
Fierce Pharma
Thu, 08/4/22 - 12:10 pm
Tags:
Amgen
,
M&A
,
patent cliff
,
ChemoCentryx
Big Pharma Is Going Holiday Shopping. Who's Next?
Motley Fool
Wed, 11/10/21 - 10:13 am
Tags:
Big Pharma
,
M&A
,
ChemoCentryx
,
Epizyme
,
Magenta Therapeutics
3 Biotech Stocks That Could Rise 90% or More, According to Wall Street
Motley Fool
Sun, 10/17/21 - 10:57 pm
Tags:
ChemoCentryx
,
Ocular Therapeutics
,
Axsome Therapeutics
Flash FDA approval sends ChemoCentryx spiralling upwards
Pharmaforum
Sun, 10/10/21 - 09:48 pm
Tags:
ChemoCentryx
,
FDA
,
avacopan
,
Tavneos
,
ANCA-positive vasculitis
The big approvals still on the cards for 2021
EP Vantage
Thu, 06/17/21 - 11:00 am
Tags:
FDA
,
drug approvals
,
Argenx
,
Novartis
,
AstraZeneca
,
Astellas
,
UCB Pharma
,
Ascendis Pharma
,
ChemoCentryx
,
Axsome Therapeutics
Adcomm splits slightly in favor of FDA approving ChemoCentryx’s rare disease drug
Endpoints
Thu, 05/6/21 - 11:06 pm
Tags:
FDA
,
advisory panels
,
ChemoCentryx
,
avacopan
,
ANCA-positive vasculitis
Chemocentryx takes a leap of faith with avacopan
EP Vantage
Thu, 10/29/20 - 12:13 pm
Tags:
ChemoCentryx
,
avacopan
,
clinical trials
,
hidradenitis suppurativa
ChemoCentryx Drug Hits Co-Primary Endpoints in Phase III Vasculitis Trial
BioSpace
Tue, 11/26/19 - 11:37 pm
Tags:
ChemoCentryx
,
Vifor Fresenius Medical Care Renal Pharma
,
avacopan
,
ANCA-positive vasculitis
,
clinical trials
Pancreatic cancer combo sees high survival rates in ChemoCentryx PhIb data
Endpoints
Tue, 01/23/18 - 02:48 pm
Tags:
pancreatic cancer
,
ChemoCentryx
,
CCX872
ChemoCentryx’s (CCXI) CCX168 Receives Orphan Drug Status
Bidness Etc.
Fri, 11/21/14 - 08:36 am
Tags:
ChemoCentryx
,
CCX168
,
orphan drugs
,
aHUS
Five Small Biotech Stocks Analysts Think Will Triple
Forbes
Thu, 05/1/14 - 07:23 am
Tags:
Arrowhead Research
,
ChemoCentryx
,
Ziopharm
,
TherapeuticsMD
,
Dynavax
3 Horrendous Health-Care Stocks This Week
Motley Fool
Sat, 09/14/13 - 11:01 am
Tags:
Neurocrine Biosciences
,
ChemoCentryx
,
GSK
,
Avanir
Neurocrine And ChemoCentryx: Phase II Data Disappoints
Seeking Alpha
Wed, 09/11/13 - 11:25 am
Tags:
Neurocrine
,
ChemoCentryx
,
CCX140
,
NBI-98854
,
tardive dyskinesia
,
diabetic nephropathy
ChemoCentryx Falls on Weak Diabetic Nephropathy Drug Data
TheStreet.com
Tue, 09/10/13 - 11:37 am
Tags:
ChemoCentryx
,
diabetic nephropathy
,
CCX140
The Impact of a Failed Crohn's Disease Trial Study
Motley Fool
Fri, 08/30/13 - 10:36 am
Tags:
Crohn's Disease
,
Vercirnon
,
ChemoCentryx
,
GSK
3 Horrendous Health-Care Stocks This Week
Motley Fool
Sat, 08/24/13 - 11:48 am
Tags:
ChemoCentryx
,
Aglos Pharmaceuticals
,
Prosensa
GSK's Crohn's disease treatment fails in Phase III trial
Reuters
Fri, 08/23/13 - 11:11 am
Tags:
GSK
,
Crohn's Disease
,
ChemoCentryx
,
Vercirnon
Pages
1
2
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.